Sangamo Therapeutics, Inc. (SGMO): Price and Financial Metrics

Sangamo Therapeutics, Inc. (SGMO)

Today's Latest Price: $10.12 USD

0.35 (3.58%)

Updated Nov 27 1:00pm

Add SGMO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

SGMO Stock Summary

  • Of note is the ratio of Sangamo Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 15.14% of US stocks have a lower such ratio.
  • SGMO's price/sales ratio is 9.72; that's higher than the P/S ratio of 84.95% of US stocks.
  • Revenue growth over the past 12 months for Sangamo Therapeutics Inc comes in at 97.87%, a number that bests 94.54% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Sangamo Therapeutics Inc, a group of peers worth examining would be GLYC, DTIL, SRRK, CMRX, and ALPN.
  • Visit SGMO's SEC page to see the company's official filings. To visit the company's web site, go to

SGMO Stock Price Chart Interactive Chart >

Price chart for SGMO

SGMO Price/Volume Stats

Current price $10.12 52-week high $13.20
Prev. close $9.77 52-week low $4.81
Day low $9.81 Volume 1,103,000
Day high $10.13 Avg. volume 1,990,243
50-day MA $10.60 Dividend yield N/A
200-day MA $9.69 Market Cap 1.43B

Sangamo Therapeutics, Inc. (SGMO) Company Bio

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. The company was founded in 1995 and is based in Richmond, California.

SGMO Latest News Stream

Event/Time News Detail
Loading, please wait...

SGMO Latest Social Stream

Loading social stream, please wait...

View Full SGMO Social Stream

Latest SGMO News From Around the Web

Below are the latest news stories about Sangamo Therapeutics Inc that investors may wish to consider to help them evaluate SGMO as an investment opportunity.

Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenneth Hillan, an accomplished biotechnology executive, to the Company's Board of Directors. "We are pleased to welcome Kenneth to the Sangamo Board of Directors," said Sandy Macrae, Chief Executive Officer of Sangamo. "We believe that Kenneth’s 25 years of clinical development and executive leadership experience, as well as his current focus on the t

Business Wire | September 11, 2020

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences: Wells Fargo 2020 Virtual Healthcare Conference Presentation Date: Thursday, September 10th at 3:20 p.m. Eastern Time Cantor Virtual Global Healthcare Conference Presentation Date: Tuesday, September 15th at 3:20 p.m. Eastern Time Morgan Stanley 18th Annual Global Healthcare Conference Presentation Date: Frid

Business Wire | September 2, 2020

How Much Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Paying Its CEO?

Sandy Macrae became the CEO of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in 2016, and we think it's a good time to look…

Yahoo Finance | September 1, 2020

The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 6) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (announced introduction of AditxtScore for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biocept Inc (NASDAQ: BIOC ) (announced an agreement with Aegea for a highly sensitive PCR-based assay designed by the latter for detecting the COVID-19 virus) DarioHealth Corp (NASDAQ: DRIO ) Denali Therapeutics Inc (NASDAQ: DNLI )( announced selection of candidate to enter Phase 3 study in Parkinson's disease) Editas Medicine Inc (NASDAQ: EDIT )(moved on M&A speculation) Emergent Biosolutions Inc (NYSE: EBS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) ITAMAR MED LTD/S ADR (NASDA...

Benzinga | August 7, 2020

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2020 Results - Earnings Call Transcript

Sangamo Therapeutics, Inc. (SGMO) Q2 2020 Earnings Conference Call August 5, 2020 17:00 ET Company Participants McDavid Stilwell - Senior Vice President, Corporate Communication and IR Sandy Macrae - Chief Executive Officer Bettina Cockroft - Chief Medical Officer Sung Lee - Chief Financial Officer Mark McClung - Chief Business Officer...

SA Transcripts on Seeking Alpha | August 6, 2020

Read More 'SGMO' Stories Here

SGMO Price Returns

1-mo -4.62%
3-mo -6.73%
6-mo -14.45%
1-year -6.30%
3-year -29.97%
5-year 22.22%
YTD 20.91%
2019 -27.09%
2018 -30.00%
2017 437.70%
2016 -66.59%
2015 -39.97%

Continue Researching SGMO

Want to see what other sources are saying about Sangamo Therapeutics Inc's financials and stock price? Try the links below:

Sangamo Therapeutics Inc (SGMO) Stock Price | Nasdaq
Sangamo Therapeutics Inc (SGMO) Stock Quote, History and News - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8046 seconds.